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Progesterone (P4) is a requirement for pregnancy development. Previous reports observed a
maximal value of serum P4 concentration on 21 days after the first mating after which it
slowly declines throughout the rest of pregnancy. Ultrasound examination should be per-
formed to ensure that pregnancy interruption is complete. Limited information is available
on the ultrasonic appearance of conceptuses during pregnancy termination in cats The
objective was to study serum P4 concentration and ultrasonographic changes during
aglepristone (ALI) or cloprostenol (CLO) treatment and to evaluate the fertility after treat-
ment. Two experiments (EXP) were carried out to accomplish this aim. Sixty queens, 12- to
36-month-old, were used. On Days 21 to 22 of pregnancy (EXP I) or 35 to 38 of pregnancy
(EXP II), queenswere divided into three groups (G). Queens in G1 received ALI (10mg/kg, sc;
EXP I, n ¼ 10; EXP II, n ¼ 10) for 2 consecutive days. Queens in G2 received CLO (5 mg/kg, sc;
EXP I, n ¼ 10; EXP II ¼ 10) for 3 consecutive days. Queens in G3 received 1 mL of saline
solution (PLA, sc; EXP I, n ¼ 10; EXP II ¼ 10). Blood samples were taken before treatment
(Day 0) and every day during 10 days after the treatment to measure serum P4 concen-
trations. Likewise, after treatment, queens were monitored daily by ultrasonography for
10 days and weekly until the end of gestation to obtain gestational sacs measurements (GS),
fetal measurements, and fetal biophysical profile. Data were analyzed by ANOVA. Serum P4
concentrations were significantly different on Day 6 (EXP I) and on Day 1 (EXP II) in ALI and
CLO groups compared with PLA group (P < 0.05 and P < 0.01; respectively). The ultraso-
nographic monitoring during treatment allowed assessing changes in the GS and fetal
measurements, embryo-fetal viability, and risk of pregnancy loss. In conclusion, the results
from this study reported changes in serum P4 concentration and in ultrasonography mea-
surements during pregnancy interruption with ALI or CLO treatment. Also it was observed
that ALI and CLO are safe drugs and can preserve posttreatment queen fertility. Therefore,
the results obtained in our work will be applied in feline reproduction practice.
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501. Introduction
Unobserved mating and unwanted pregnancy is com-
mon in sexually mature queens with outdoor access. In
queens, pregnancy is usually detected on routine clinical
examination during early or middle gestation. Several
methods for pregnancies termination in queens have been
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has been reported that luteal function is dependent on
prolactin support in middle and late gestation (between
Days 34 and 42 of pregnancy; [1]). In addition, feline
placenta is a source of progesterone (P4) and can maintain
pregnancy after Day 45 of gestation [2]. Thus, dopaminergic
agents such as cabergoline have been used for induction of
abortion after Day 30 of pregnancy to reduce serum
prolactin concentrations but failed when started at Day 45
[1,3]. Combined treatment with prostaglandin analogues
such as cloprostenol (CLO) or alfaprostol and cabergoline
was more successful and side effects were significantly
reduced [1,4]. Prostaglandin F2a administration at Day 33
of pregnancy induces luteolysis and pregnancy termination
with expulsion of fetuses [5]. Another alternative to induce
abortion is the use of antiprogestins, such as aglepristone
(ALI). Treatment with ALI has been proven to be safe and
effective for early, middle, and late pregnancy termination
in the queen [6–11].
Progesterone is a requirement for pregnancy develop-
ment [12]. García Mitacek et al., [13] observed a maximal
value of serum P4 concentration on 21 days after the first
mating after which it slowly declines throughout the rest of
pregnancy. These findings are in agreement with
Zschockelt et al. [14], who found that intraluteal P4 con-
centrations were higher during development/maintenance
(Day 14–36) compared to the regression luteal stages dur-
ing the pregnancy (Day 38–63). In addition, identical
intraluteal expression profiles of steroidogenic enzymes, as
well as intraluteal contents of steroids, suggest that an
on-going loss of steroidogenic capacity similarly causes a
functional demise of the CL [14].
Ultrasonography is a noninvasive technique that per-
mits an accurate diagnosis of pregnancy and allows serial
evaluation of the developing embryo/fetus and extrafetal
structures [15]. In addition, an ultrasound examination
should be performed to ensure that pregnancy interruption
is complete. Although several researchers have done many
ultrasonography studies on queen pregnancy, limited
information is available on the ultrasonic appearance of
conceptuses during pregnancy termination in cats.
Fetal biophysical profile (FBP) scoring is used to predict
the presence or absence of fetal hypoxia [16]. The FBP was
developed by Manning et al. [17] in 1980 to evaluate the
gestation in the woman. The original method of fetal bio-
physical profile scoring was based on a composite assess-
ment of five variables: fetal breathing, gross body
movements, tone, heart rate acceleration with fetal move-
ment and amniotic fluid volume evaluated by real-time
ultrasonography [16]. The FBP is noninvasive and easily
applied, can be objectively evaluated, uses universally
available equipment, and is highly accurate for predicting
the presence of significant fetal hypoxemia or acidemia,
which is indicative of fetal morbidity. A normal score pre-
dicts no fetal compromise and allows for conservative
management in a gestation with high-risk factors, such as
diabetes mellitus or hypertension. In contrast, an abnormal
score in a similarly high-risk patient allows for weighing of
relative fetal-neonatal risks and selection of delivery at a
time when the balance shifts to greater fetal risk [16,17]. To
our knowledge, the use of FBP during the pregnancy inqueens has not been studied. Thus, the study of FBP in
queens to predict the presence or absence of fetal
compromise could be potentially useful in practice because
it could provide important information for fetal surveil-
lance in high-risk gestations in queens. In the same way,
clinical management based on the FBP score could reduce
perinatal mortality.
The aim of the study was to study serum P4 concen-
tration and ultrasonographic changes during treatment
with ALI or CLO and evaluate posttreatment fertility. Two
experiments (EXP) were carried out to accomplish this
objective. The hypothesis was that serum P4 concentration
and conceptus ultrasonographic changes could be detected
during the treatment with ALI or CLO and that both treat-
ments would not interfere with subsequent fertility.2. Materials and methods
Mixed breed queens (n ¼ 60), age between 12 and
36 months and weighting between 2 and 4 kg, were used
in a randomized design [18]. In addition, two 3-year-old
intact tomcats were used for breeding. The queens were
housed in individual stainless steel cages and were fed
commercial cat food (Fit 32; Royal Canin, Buenos Aires,
Argentina) and water ad libitum. A physical examination of
all animals included in the study was performed once a
week. The toms were housed separately from queens and
fed the same diet. All animals were maintained in a
controlled environment with artificial incandescent illu-
mination (14 hours of daily bright light; [19]). Animal care,
housing, and experimentation complied with International
Guiding Principles for Biomedical Research Involving
Animals [20] and the approval of the IACUC of FCV UNLP
(26-3-12). Queens were observed on a daily basis to detect
estrous behavior, and receptivity to the male and vaginal
cytology was performed to detect cytological estrus. When
queens reported behavioral and cytological estrus, each
queen was placed with the tom for 48 hours. The first
mating was documented, and pregnancies were confirmed
by abdominal palpation and transabdominal ultrasono-
graphic examination using an ultrasound scanner equip-
ped with a 5- to 7.5- to 10-MHz linear transducer
(MindrayTM, DP-6600 Vet, Nashan, China) 20 days after
the first mating [15].
On Days 21 to 22 of pregnancy (EXP I) or 35 to 38 of
pregnancy (EXP II), queens were divided into three groups
(G). In G1, animals received 10-mg/kg ALI sc (Alizin, Virbac,
Germany, ALI; EXP I, n¼ 10; EXP II, n¼ 10) on 2 consecutive
days. In G2, animals received 5-mg/kg CLO sc (Ciclar p.a. ,
Zoovet, Argentina, CLO; EXP I, n ¼ 10; EXP II, n ¼ 10) on 3
consecutive days. In G3, animals received 1 mL of saline
solution sc (PLA; EXP I, n ¼ 10; EXP II, n ¼ 10). Blood
samples were taken before administration the treatment
(Day 0), during the treatment, and every day thereafter
until Day 10 to measure serum P4 concentrations. All blood
samples were centrifuged and stored at20 C until P4 was
measured by solid RIA using I125 (Coat-A-Count, proges-
terone; Diagnostic Product Corporation, Los Angeles, CA,
USA). The intraassay CVs for high-pool (6.8 ng/mL) and
low-pool P4 (0.9 ng/mL) were 3.9, and 5.4%, respectively.
Fig. 1. (A). Day 21 of pregnancy, ultrasound section of gestational sac (GS). Longitudinal dimensions of GS: caliper one, length (LEN, mm); caliper two, anterior-
posterior (ATP, mm). Ultrasound scanner with a 7.5-MHz linear transducer. (B). Day 21 of pregnancy, ultrasound section of gestational sac (GS). Transverse
dimensions of GS: caliper one, width (WID, mm); caliper two, uterine wall thickness (UW, mm). Ultrasound scanner with a 7.5-MHz linear transducer.
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sonography for 10 days and weekly until the end of gesta-
tion to obtain gestational sacs (GS) and fetal measurements.
Food and water were not restricted prior to the ultrasound
examination. Transabdominal ultrasonographic examina-
tions were performed with the queens positioned in dorsal
recumbency. The queens were not sedated or anesthetized.
Before the first ultrasonographic examination and every
5 days, the hair on the ventral abdomen was clipped.
Acoustic coupling gel was applied to the skin of the ventral
abdomen. The abdomen was scanned just cranial to the
pubis, where the bladder and colon were identified as
landmarks for the uterus. Once located; the uterine body,
bifurcation, and horns were scanned in a transverse and
sagittal plane. Dimensional measurements of GS were
made and recorded fromgestational Day 21 to 22 to 10 days’
after treatment (EXP I) and GS, fetal measurements, and
fetal biophysical profile scoreweremade and recorded from
gestational Day 35 to 38 to 10 days’ after treatment (EXP II).
All measurements were made with electronic calipers from
appropriate frozen images. At each examination, two sets of
images of GS and fetal measurements were recorded for
each queen, regardless of number of fetuses present.
During each ultrasound examination, GS were
measured from longitudinal and transverse images. From
longitudinal images, the length (LEN, mm) and anterior-
posterior (ATP, mm) dimensions of GS were measured.
From transverse images, the width (WID, mm) dimension
of GS was measured. The GS volume (GSV, mm3) was
calculated by the prolate ellipse formula (4/3p*[GSLEN/2]*
[GSATP/2]*[GSWID/2]) and GS diameter (GSD, mm) wascalculated averaging three orthogonal measurementsmade
from frozen images. In addition, the uterine wall thickness
(UW; Fig. 1A, B) was measured [13,16]. During the treat-
ment, ultrasound changes in cavity reduction and particles
fill up in the GS were evaluated (Tables 1 and 2).
Fetal measurements included crown-rump length (CRL),
head diameter (HD), and body diameter (BD). The CRL
length was measured along the longest axis of the fetus
[13,21]. Transverse HD was measured from a dorsal plane
image. Image quality of HD was initially assessed by a
symmetric frontal scanning of the skull with an evident falx
cerebri; and the BD was measured from a transverse image
of the abdomen at the level of the stomach, as previously
described by Beck et al [13,22] (Fig. 2A–C).
Fetal biophysical profile is a score ad hoc derived from
observation of three discrete dynamic fetal biophysical
variables (fetal heart rate [FHR] in heartbeats per minute,
gross body movement [GBM], and GSV). The score can
range from 6/6 (all variables normal) to 0/6 (all variables
abnormal; Table 3) [16,17,21]. The normal number of GBM
was calculated in PLA group. Daily, the fetuses were
observed by ultrasonography and fetal movements were
recorded during a minute. Ultrasonographic examinations
were performed by MCGM.
When the treatment finished, returned to the estrus
after pregnancy interruption or parturition we registered.
In the second estrus, each queen was placed with the tom
for 48 hours. The first mating was documented, and preg-
nancies were confirmed by abdominal palpation and
transabdominal ultrasonographic examination 20 days
after the first mating.
Table 1
The ultrasound scoring system of particles in the gestational sacs (PGS).
Score Description Ultrasound image
0 Normal GS
1 The particles fill up to 25% of the GS
2 The particles fill up to 50% of the GS
3 The particles fill up to 75% of the GS
Abbreviation: GS, gestational sac.
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Data are shown as least squares means  standard
errors. Statistical significancewas set at P< 0.05. The queen
was considered the experimental units.
Ultrasonographic measurement of the GS (LEN, ATP,
WID, GSV, GSD, UW, particles in the gestational sacs [PGS],
and reduction of the gestational sacs [RGS]), fetal mea-
surements (CRL, HD, and BD), FBP (FHR, GBM, and GSV),
and serum P4 concentrations were analyzed by PROC
MIXED from SAS 9.1 as repeated measures [23]. The model
included the random effect of the queen and the fixed
effects of time (days of treatment, treatment [ALI vs. CLO vs.
PLA], and interaction of treatment by day of treatment). A
polynomial contrast was used to test the linear, quadratic,
and cubic effects [18]. The area under the curve (AUC) was
analyzed by Sigma plot 10.0 [24].
Days of gestation (DG), days from treatment to the
presence of vulvar discharge (DTDV), days from pregnancy
interruption to the return to estrus were analyzed by the
PROC GLM of SAS 9.1 [23]. The logistic model included the
fixed effect of treatment and days of treatment. The num-
ber of kittens was analyzed with PROC GENMOD of SAS 9.1
with Poisson regression and log link functions [23]. Thelogistic model included the fixed effect of treatment and
days of treatment. Statistical analysis was performed by
MCGM and RLS.
3. Results
3.1. EXP I
While all queens treated with ALI terminated pregnancy
(10/10, 100%), none of those treated with CLO- (0/10, 0%) or
with PLA (0/10, 0%) terminated pregnancy (P< 0.0001). The
interval from treatment to first signs of pregnancy termi-
nation in the ALI group was significantly shorter than the
interval from treatment to the end of a normal pregnancy
in the CLO- and PLA-treated queens (4.30  0.60 vs.
43.2  0.60 vs. 43.0  0.60 days, P < 0.001). One queen of
the ALI group had three GS on Day 21, two of them began a
pregnancy interruption at 4 days after beginning the
treatment. However, one fetus remained intrauterine
which was aborted 42 days after beginning the treatment.
The average DG for queens with normal pregnancy were
similar in CLO and PLA groups (64.6  0.61 vs.
64.2  0.61 days, P > 0.65). The number of GS at the
beginning of the study was similar in ALI, CLO, and PLA
Table 2
The ultrasound scoring system of reduction of the gestational sacs (RGS).
Score Description Ultrasound image
0 Normal GS
1 Reduction of up to 25% of the GS
2 Reduction of up to 50% of the GS
3 Reduction of up to 75% of the GS
4 Reduction of up to 100% of the GS
Abbreviation: GS, gestational sac.
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respectively). The number of kittens born from normal
pregnancies was similar in the CLO- and PLA-treated group
(3.7 0.29 vs. 3.2 0.29, P> 0.24), and 100% of the animals
wereweaned. The interval from the beginning of treatment
to presence of vulvar discharge in the ALI group was
7.42  0.92 days.
Serum P4 concentration was not significantly different
between ALI, CLO, and PLA group at beginning of the
treatment (22.92 2.41, 23.4 2.41, and 29.4 2.54 ng/mL,
respectively). On Day 6 in ALI and CLO groups, serum P4
concentrationwas significantly different than in PLA group.
The main effect of treatment, and the interaction of treat-
ment by day and treatment by serum P4 concentrations
were significant (40.90  2.65, 19.40  2.17, and
29.25 2.30 ng/mL, P< 0.0001; respectively). Twenty-fourhours after the treatment, serum P4 concentrations were
significantly lower in CLO group comparedwith ALI and PLA
(14.47  2.17, 28.39  2.17, and 29.36  2.17; P < 0.005
respectively). On Day 9 after the treatment, no significant
difference in serum P4 concentrations were observed
between ALI, CLO, and PLA groups (Fig. 3). The AUC serum
P4 concentrationwere smaller in CLO group than in ALI and
PLA group from Day 0 to Day 5 after treatment
(61.96  13.72 ng d/mL vs. 156.99  14.47 ng d/mL,
P < 0.001). However, during the same period, the AUC of
serum P4 concentration was similar between ALI and PLA
group (166.06  14.47 ng d/mL vs. 147.92  14.47 ng d/mL,
P> 0.38). The AUC serum P4 concentrations were smaller in
CLO group than in ALI. Furthermore, from Day 5 to Day 8
after the treatment, the AUC serum P4 concentrations were
smaller in CLO group than in ALI and PLA group
Fig. 2. (A). Day 36 of pregnancy. Crown-rump length: caliper one (CRL, mm). Ultrasound scanner with a 10-MHz linear transducer. (B). Day 36 of pregnancy. Head
diameter: caliper one (HD, mm). Ultrasound scanner with a 10-MHz linear transducer. (C). Day 36 of pregnancy. Body diameter: caliper one (BD, mm). Ultrasound
scanner with a 10-MHz linear transducer.
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P < 0.001). However, during the same period, the AUC
serum P4 concentrations were smaller in CLO group than in
ALI. The AUC serum P4 concentrations were smaller in CLO
group than in ALI. The AUC serum P4 concentration were
greater in ALI group than PLA group (156.1616.31 ng d/mL
vs. 86.41  9.98 ng d/mL, P < 0.001).
At the start of the study, all GS measurements were
similar for all treatment groups (LEN [P > 0.85], ATP
[P > 0.54], WID [P > 0.17], GSV [P > 0.24], and GSDTable 3
Biophysical profile scoring: technique and interpretation.
Biophysical
variable
Normal (score 2) Abnormal (score 0)
FHR 220 bpm <220 bpm
GBM 7 movements in 1 min <7 movements in 1 min
GSV Increase Decrease or maintain
Abbreviations: bpm, heartbeat per minute; FHR, fetal heart rate; GBM,
gross body movement; GSV, gestational sac volume.
Days posttreatment
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Fig. 3. Least squares means  standard errors of P4 (ng/mL) during PLA, ALI
(10 mg/kg, on 2 consecutive days), or CLO (5 mg/kg, on 3 consecutive days)
treatment at 21 to 22 days of gestation. Superscripts differ at P < 0.05. ALI,
aglepristone; CLO, cloprostenol.
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Fig. 4. Least squares means  standard errors of dimensions LEN (mm, A),
ATP (mm, B), WID (mm, C) of SG during PLA, ALI (10 mg/kg, on 2 consecutive
days), or CLO (5 mg/kg, on 3 consecutive days) treatment at 21 to 22 days of
gestation. Superscripts differ at P < 0.05. ALI, aglepristone; ATP, anterior-
posterior; CLO, cloprostenol; LEN, length; WID, width.
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Fig. 5. Least squares means  standard errors of dimensions GSV (mm3, A),
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gestation. Superscripts differ at P < 0.05. CLO, cloprostenol; GS, gestational
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GSD) increased at different rate among treatments across
DG (interaction of treatment by day of gestation;
P < 0.0001, Figs. 4 and 5). In the group of queens that
pregnancy was terminated (ALI), all GS measurements did
not increase after treatment. To the contrary, in the groups
with normal pregnancy (CLO and PLA), GS measurements
continued to increase during the next 10 days aftertreatment (P < 0.01, Figs. 4 and 5). At the start of the study,
UW was similar for all treatment groups (P > 0.31). How-
ever, the UWwas greater in ALI vs. CLO or PLA group at Day
3 and Days 5 to 11 (Fig. 5). In addition, at the beginning of
the treatment, PGS and RGS were similar for all treatment
groups. Particles in the gestational sacs increased after the
treatment in the ALI group and were higher than CLO and
PLA groups at all time points (P< 0.0001). Reduction of the
gestational sacs also increased after the treatment in the
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differ at P < 0.05. ALI, aglepristone; CLO, cloprostenol; GS, gestational sac.
Days posttreatment
0 1 2 3 4 5 6 7 8 9 10 11
Pr
og
es
te
ro
ne
 (n
g/
m
L)
0
10
20
30
40
50
Aglepristone
Cloprostenol
Saline solution
A
A A
A
A
A
A
B
B B
B
B
Fig. 7. Least squares means  standard errors of P4 (ng/mL) during PLA, ALI
(10 mg/kg, on 2 consecutive days) or CLO (5 mg/kg, on 3 consecutive days)
treatment at 35 to 38 days of gestation. Superscripts differ at P < 0.05. ALI,
aglepristone; CLO, cloprostenol; P4, progesterone.
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Day 2 after the treatment (P < 0.0001; Fig. 6).
The return to estrus after pregnancy termination or after
normal pregnancy was similar in ALI, CLO, and PLA groups
(62.8  8.69, 49.0  8.69, 57.8  8.69 days, P > 0.53;
respectively). Treatment did not affect the subsequent
fertility in both ALI and CLO groups, since the queens
became pregnant (pregnancy rate 100%) in the first mating
after the treatment. The average DG were similar in the ALI
and CLO group (64.8  0.62 vs. 65.0  0.62 days, P > 0.82).
The number of kittens born from normal pregnancies was
similar in the ALI and CLO group (2.8  0.31 vs. 3.3  0.31,
P > 0.27) and 100% of the animals were weaned.
After CLO administration, all animals vomited and were
depressed for 30 minutes. No side effects were seen with
ALI-treated animals.
3.2. EXP II
While all queens treated with ALI terminated pregnancy
(10/10,100%), only one treatedwith CLO (1/10,10%) aborted
5 days after the beginning of the treatment, and none of
PLA (0/10, 0%) reported abortion (P < 0.0001). The interval
from treatment to pregnancy termination was similarbetween ALI- and CLO-treated queens (4.1  0.31 vs. five
days, P > 0.41). The interval from the beginning of treat-
ment to presence of vulvar discharge in aborted queen was
similar between ALI and CLO groups (4.0  0.29 vs. 3 days,
P > 0.33). The average DG for queens with normal preg-
nancy were similar in CLO and PLA groups (65.0  0.46 vs.
65.2  0.44 days, P > 0.76). The number of kittens born
from normal pregnancies was similar in the CLO and PLA
group (3.44  0.41 vs. 3.5  0.39, P > 0.93) and 100% of the
kittens were weaned.
Serum P4 concentration was not different between ALI,
CLO, and PLA group at the beginning of the treatment
(32.25  2.8, 32.2  2.96, and 32.96  2.8 ng/mL, P > 0.99).
On Day 1 in ALI and CLO groups, serum P4 concentrations
were significantly different than in PLA group. The main
effect of treatment, and the interaction of treatment by day,
and treatment by serum P4 concentrations were significant
(37.80  2.80, 19.16  2.96, and 26.43  2.80 ng/mL,
P < 0.0001; respectively). Twenty-four hours after the
treatment, serumP4 concentrationswere significantly lower
in CLO group compared with ALI and PLA (19.16  2.96,
37.5 2.80, and 26.43 2.80; P< 0.01 respectively). On Day
8 after the treatment, no significant difference in serum P4
concentrations were observed between ALI, CLO, and PLA
groups (Fig. 7). From Day 0 to Day 5 after the treatment, the
AUC of serum P4 concentration was smaller in CLO group
than in ALI and PLA group (67.55  19.5 ng d/mL vs.
171.86  18.53 ng d/mL, P < 0.001). However, during the
same period, the AUC of serumP4 concentrationwas greater
in ALI group than PLA group (207.85  18.53 ng d/mL vs.
135.88  18.53 ng d/mL, P < 0.01). From Day 5 to Day seven
after the treatment, the AUC of serum P4 concentration was
smaller in CLO group than in ALI and PLA group
(31.02  7.34 ng d/mL vs. 55.95  7.15 ng d/mL, P < 0.009).
However, during the same period, the AUC of serum P4
concentration was greater in ALI group than PLA group
(58.63  7.34 ng d/mL vs. 53.28  6.96 ng d/mL, P < 0.60).
One day after treatment initiation, there were no sig-
nificant differences in GS (LEN [P > 0.22], ATP [P > 0.88],
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measurements (CRL [P > 0.70], HD [P > 0.06] and BD
[P > 0.44]) among treatments (P > 0.05). The GS and fetal
measurements (LEN, ATP, WID, GSV, GSD, CRL, HD, and BD)
increased at different rates among treatments across DG
(interaction of treatment by day of gestation; P < 0.0001,
Figs. 8–10). In addition, PLA-treated animals had a greater
increase of GS and fetal measurements compared ALI- and
CLO-treated animals (P > 0.05). Although in ALI and CLOgroups, GS and fetal measurements increased after treat-
ment (P > 0.05), there were no significant differences
between GS and fetal measurements between ALI group
and the queen that aborted in CLO group (P > 0.05). At the
start of the study, UW was similar for all treatment groups
(P > 0.12). In the ALI group, UW was significantly higher at
Day 4 after the treatment than PLA group (Fig. 9).
The average of the GBM recorded in PLA group was 7
movements in 1 minute. No significant differences were
observed in the FHR and GBM between ALI, CLO, and PLA
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1.77 0.17, P > 0.62], [GBM 1.0  0.33, 1.10.35, 1.10.35,
P > 0.96]; respectively). Similar results were obtained in
the GSV between CLO and PLA groups (1.5  0.29 vs.
1.7  0.29 P > 0.59; respectively). On the contrary, signifi-
cant differences were observed in the GSV between ALI and
PLA groups (0.8  0.27 vs. 1.77  0.29, P > 0.02; respec-
tively). However, no significant differences were obtainedin the FBP between ALI, CLO, and PLA groups (3.6  0.46,
4.6  0.49, 4.6  0.49, P > 0.20; respectively).
The return to estrus after pregnancy termination or
parturition was similar in ALI, CLO, and PLA groups
(34.4  5.84, 40.42  6.98, 43.3  5.84 days, P > 0.55;
respectively). Treatment did not interfere with subsequent
fertility in both ALI and CLO groups, since the queens
became pregnant (pregnancy rate 100%) in the first mating
after the treatment. The average DG were similar in the ALI
and CLO group (65.0  0.67 vs. 64.2  0.75 days, P > 0.47).
The number of kittens born from normal pregnancies was
similar in the ALI and CLO group (2.6  0.22 vs. 2.5  0.25,
P > 0.77) and 100% of kittens were weaned.
After CLO administration, all animals vomited and were
depressed for 30 minutes. No side effects were seen with
ALI treated animals.
4. Discussion
According to our hypothesis, we obtained changes in
serum P4 concentration and ultrasonographic images dur-
ing the treatment with ALI and CLO. The efficacy of CLO and
ALI for pregnancy termination observed in the present
work is in agreement with results previously obtained by
García Mitacek et al. [11].
Fiéni et al. [9] reported that ALI administration produces
a significant increase in P4 concentrations after 60 hours
after administration. According with Fiéni study, we
observed an increase in serum P4 concentrations after ALI
administration and P4 remained high during 8 or 5 days
after the treatment (21–22 days or 35–38 days treatment,
respectively). This observation is also in agreement with
previous reports in which the use of ALI acts as a true P4
antagonist on the uterus, thereby modifying serum P4
concentrations inducing pregnancy termination, without
any immediate effects on luteal function [9,25,26].
In contrast in CLO group, serum P4 concentration
quickly declined 24 hours after initiation of treatment.
However, in CLO group 4 days after treatment, P4 levels
began to rise, and 8 days after treatment the serum P4
concentrations were similar to PLA group. The decline of
serum P4 after prostaglandin administration observed in
our work is in agreement with Shille and Stabenfeldt’s [27]
findings, who reported a decreased in serum P4 concen-
tration and consequent depression of luteal function after
PGF 2a administration in pseudopregnant queens. In the
same way, other works have reported a decrease on serum
P4 after natural or synthetic PG administration in queens
[1,4,5]. In agreement with Braun et al. [2] and Siemieniuch
et al. [28], in our work CLO group serum P4 concentrations
increased 4 days after treatment and a complete develop-
ment of pregnancy occurred. These findings which confirm
the existence of a placental source of P4 were able to
maintain pregnancy in queens. Likewise, recent findings on
PGF metabolites in feces of domestic felids support a
similar theory of different types of luteolysis in domestic
cats. During the last 20 days of pregnancy, a significant
increase in fecal PGF metabolites concentrations was
observed, showing a luteolytic action of prostaglandin F2a.
The first measurable increase in fecal PGF metabolites was
found 4 weeks before parturition and coincides with the
M.C. García Mitacek et al. / Theriogenology 88 (2017) 106–117116decrease in P4 concentration and appearance of cellular
degradation in CL [29].
Although there are several studies on pregnancy inter-
ruption using different medical protocols, there has been no
systematic description of the ultrasonic appearance of feline
fetuses during pregnancy termination. Conversely, in this
study, several ultrasonographic measurements were recor-
ded to evaluate the embryo/fetal development and viability.
Furthermore, data generated in this study could be useful to
assess the risk of pregnancy loss inpractice. In the sameway,
themeasurement of serum P4 concentration could be useful
to evaluate a normal luteal function and pregnancy devel-
opment. The results obtained in ourwork, allowed detection
of ultrasonographic and endocrinological changes after
early- or mid-gestation interruption. Therefore, our results
will be useful in feline reproductionpractice. Early detection
of fetal growth abnormalities allows to perform medical
care. Thus, ultrasonographic and endocrinological studies
throughout feline pregnancy are important for pregnancy
monitoring and early medical intervention.
The FBP is used in pregnancy woman at high risk,
allowing to estimated and reduce perinatal mortality and
morbidity [17]. In contrast, in our work, we could not
identify changes in relation with pregnancy interruption
using FBP. The differences could be related with the num-
ber and frequency of observations. On the other hand,
women have singleton pregnancies, whereas queens had
multiple pregnancies. This fact makes difficult sequential
ultrasonographic measurements in each fetus.
In our work, CLO-treated queens reported side effects
reported in association with administration of PG [30]. A
decline of PG side effects with repeated doses of the drug
was reported in canines by Verstegen [31]. The same pro-
tocol could be used in queens to reduce the side effects
associated with the administration of PG. In contrast, no
side effects were found in the animals treated with ALI.
However, in the study by Fiéni et al. [9], a small number of
queens reported inflammation at the site of ALI injection,
whereas four cats reported anorexia, depression, agitation,
and diarrhea in the first 7 days of the treatment.
In our study, all treated queens returned to estrus after
the treatment and became pregnant. Consistent with our
results, Stabenfeldt and Shille [27] reported in queens
treated with PG during pseudopregnancy a high pregnancy
rate and normal parturition. Similar results reported by
Fiéni et al. [9] who observed that all treated queens
returned to estrus, 77% became pregnant in the post-
abortion heat and 10% in the second heat. Similarly, Onclin
and Verstegen [4] have reported, queen fertility was not
affected after a combined treatment with cabergoline and
CLO. However, only 33% of the queens became pregnant
after using a combined treatment with cabergoline and
alfaprostol [1].
In conclusion, the results from this study indicate that
data from ultrasonographic measurements made in the GS
and fetuses are useful to detect changes of early- or mid-
gestation interruption. In addition, the results show that
administration of ALI or CLO during early- or mid-gestation
did not impact fertility in the queen.
The changes observed in GS like presence and amount of
particles and reduction of GS could be useful to detect earlyembryo-fetal distress and identify the risk of early- or mid-
gestation pregnancy loss.
Therefore, the results obtained in our work could be
applied in feline reproduction practice both to monitoring
pregnancy health and medical gestation interruption for
unwanted pregnancy.
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